Parmley W W
Division of Cardiology, University of California, San Francisco 94143-0124.
Am Heart J. 1990 Dec;120(6 Pt 1):1408-13. doi: 10.1016/0002-8703(90)90256-w.
The calcium antagonists are a heterogeneous class of drugs used to treat a number of cardiovascular disorders. A new generation of calcium antagonists under development have a higher degree of selectivity for vascular smooth muscle and coronary vasculature compared with verapamil, nifedipine, and diltiazem. The clinical relevance of vasoselectivity and its impact on drug selection are discussed. The newer calcium antagonists are important alternatives to older agents and may be associated with improved tolerance and a reduced incidence of adverse effects. Their place in therapy has yet to be defined by comparative studies of efficacy and safety.
钙拮抗剂是一类用于治疗多种心血管疾病的异质性药物。与维拉帕米、硝苯地平和地尔硫䓬相比，正在研发的新一代钙拮抗剂对血管平滑肌和冠状血管具有更高的选择性。本文讨论了血管选择性的临床相关性及其对药物选择的影响。新型钙拮抗剂是老一代药物的重要替代药物，可能具有更好的耐受性和更低的不良反应发生率。它们在治疗中的地位还有待通过疗效和安全性的比较研究来确定。
